De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Elutia Beheer

Beheer criteriumcontroles 3/4

De CEO Elutia's is Randy Mills, benoemd in Jun2022, heeft een ambtstermijn van 2.33 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 2.05M, bestaande uit 29.3% salaris en 70.7% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.75% van de aandelen van het bedrijf, ter waarde $ 967.51K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.5 jaar en 6.5 jaar.

Belangrijke informatie

Randy Mills

Algemeen directeur

US$2.1m

Totale compensatie

Percentage CEO-salaris	29.3%
Dienstverband CEO	2.3yrs
Eigendom CEO	0.7%
Management gemiddelde ambtstermijn	2.5yrs
Gemiddelde ambtstermijn bestuur	6.5yrs

Recente managementupdates

Recent updates

Elutia Inc.'s (NASDAQ:ELUT) Share Price Boosted 28% But Its Business Prospects Need A Lift Too

Jun 28

News Flash: 2 Analysts Think Elutia Inc. (NASDAQ:ELUT) Earnings Are Under Threat

Mar 10

Elutia Inc.'s (NASDAQ:ELUT) Share Price Is Matching Sentiment Around Its Revenues

Feb 21

Little Excitement Around Aziyo Biologics, Inc.'s (NASDAQ:AZYO) Revenues As Shares Take 63% Pounding

Apr 17

Aziyo Biologics appoints Williams as Chief Scientific Officer

Aug 26

Aziyo Biologics names co-founder C. Randal Mills as permanent CEO

Aug 10

Analyse CEO-vergoeding

Hoe is Randy Mills's beloning veranderd ten opzichte van Elutia's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$70m
Mar 31 2024	n/a	n/a	-US$49m
Dec 31 2023	US$2m	US$600k	-US$41m
Sep 30 2023	n/a	n/a	-US$32m
Jun 30 2023	n/a	n/a	-US$35m
Mar 31 2023	n/a	n/a	-US$38m
Dec 31 2022	US$2m	US$321k	-US$36m
Sep 30 2022	n/a	n/a	-US$39m
Jun 30 2022	n/a	n/a	-US$37m
Mar 31 2022	n/a	n/a	-US$28m
Dec 31 2021	US$146k	n/a	-US$25m
Sep 30 2021	n/a	n/a	-US$21m
Jun 30 2021	n/a	n/a	-US$23m
Mar 31 2021	n/a	n/a	-US$26m
Dec 31 2020	US$142k	n/a	-US$25m

Compensatie versus markt: De totale vergoeding ($USD 2.05M ) Randy } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 667.78K ).

Compensatie versus inkomsten: De vergoeding van Randy is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Randy Mills (52 yo)

2.3yrs

Tenure

US$2,050,887

Compensatie

Dr. C. Randal Mills, Ph D., also known as Randy, has been Director of Elutia Inc. (formerly known as Aziyo Biologics, Inc.) since November 2015. Dr. Mills serves as a Member of Advisory Board at eXpanded e...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
C. Mills	Co-Founder	2.3yrs	US$2.05m	0.75% $ 967.5k
Matthew Ferguson	Chief Financial Officer	4.1yrs	US$521.08k	0.91% $ 1.2m
Michelle Williams	Chief Scientific Officer	2.2yrs	US$485.97k	0.18% $ 228.0k
Erica Elchin	Vice President of Global Operations	2yrs	geen gegevens	geen gegevens
Courtney Guyer	Vice President of Marketing	6.8yrs	geen gegevens	geen gegevens
Sonali Fonseca	VP & Head of Emerging Businesses	2.8yrs	geen gegevens	geen gegevens
Jeffry Hamet	Senior VP of Finance	no data	geen gegevens	geen gegevens

2.5yrs

Gemiddelde duur

52yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van ELUT wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.5 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
C. Mills	Co-Founder	8.9yrs	US$2.05m	0.75% $ 967.5k
Kevin Rakin	Independent Chairman & Lead Independent Director	8.9yrs	US$254.61k	0.27% $ 346.0k
Brigid Makes	Independent Director	4.1yrs	US$116.41k	0.0059% $ 7.6k
Matt Zuga	Independent Director	8.9yrs	US$80.99k	0% $ 0
Maybelle Jordan	Independent Director	4.1yrs	US$96.41k	0% $ 0
David Colpman	Independent Director	2yrs	US$93.91k	0% $ 0

6.5yrs

Gemiddelde duur

63yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van ELUT wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.5 jaar).

Elutia Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Chief Financial Officer exercised options to buy US$359k worth of stock.

Co-Founder exercised options and sold US$67k worth of stock

Elutia Inc., Annual General Meeting, Jun 06, 2024

Aziyo Biologics, Inc. Appoints David Colpman to Board of Directors and Audit Committee

Aziyo Biologics, Inc. Promotes Jeff Hamet to Senior Vice President of Finance

Aziyo Biologics, Inc. Appoints Michelle Leroux Williams, Ph.D as Chief Scientific Officer

Recent updates

Elutia Inc. Announces New Peer Reviewed Publication Highlighting the Robustness of Elupro™, Company’S Antibiotic-Eluting Bioenvelope for Implantable Devices

Consensus EPS estimates fall by 71%

New major risk - Financial position

New major risk - Share price stability

New minor risk - Market cap size

Chief Financial Officer exercised options to buy US$359k worth of stock.

Elutia Inc. to Report Q2, 2024 Results on Aug 07, 2024

Elutia Inc.'s (NASDAQ:ELUT) Share Price Boosted 28% But Its Business Prospects Need A Lift Too

New major risk - Shareholder dilution

Price target increased by 60% to US$8.00

Elutia Inc. Announces FDA Clearance of EluPro®

Co-Founder exercised options and sold US$67k worth of stock

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Elutia Inc. to Report Q1, 2024 Results on May 09, 2024

New major risk - Shareholder dilution

Elutia Inc., Annual General Meeting, Jun 06, 2024

New major risk - Shareholder dilution

News Flash: 2 Analysts Think Elutia Inc. (NASDAQ:ELUT) Earnings Are Under Threat

Full year 2023 earnings: EPS and revenues miss analyst expectations

New major risk - Revenue and earnings growth

Elutia Inc. to Report Q4, 2023 Results on Mar 07, 2024

Elutia Inc.'s (NASDAQ:ELUT) Share Price Is Matching Sentiment Around Its Revenues

Elutia Submits CanGaroo Antibiotic-Eluting Biomatrix for FDA Clearance

Consensus revenue estimates increase by 17%

Elutia Notifies the Nasdaq Stock Market LLLC That the Company Was Not in Compliance with Listing Rule 5605(B)(1)

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Revenue and earnings growth

Berkeley Biologics, LLC completed the acquisition of Orthobiologics business unit of Elutia Inc. (NasdaqCM:ELUT).

Elutia Inc. Receives A Delisting Determination Letter from Listing Qualifications Department of Nasdaq

Elutia Inc. to Report Q3, 2023 Results on Nov 13, 2023

Elutia Inc. announced that it has received $10.5 million in funding from HighCape Partners Management, L.P., Nantahala Capital Management, LLC

New major risk - Shareholder dilution

Berkeley Biologics, LLC entered into an Asset Purchase Agreement Orthobiologics business unit of Elutia Inc. (NasdaqCM:ELUT) for $35 million.

Consensus revenue estimates increase by 12%, EPS downgraded

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Aziyo Biologics, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Consensus revenue estimates decrease by 25%, EPS upgraded

Aziyo Biologics, Inc. Announces the Voluntary Recall of Its Viable Bone Matrix Products

Price target decreased by 17% to US$10.00

Aziyo Biologics, Inc. Presents Positive Clinical Data on Cangaroo® Biologic Envelope

First quarter 2023 earnings released: US$0.49 loss per share (vs US$0.60 loss in 1Q 2022)

Aziyo Biologics, Inc. to Report Q1, 2023 Results on May 10, 2023

Little Excitement Around Aziyo Biologics, Inc.'s (NASDAQ:AZYO) Revenues As Shares Take 63% Pounding

Full year 2022 earnings released

Aziyo Biologics, Inc. Provides Preliminary Sales Guidance for the Fourth Quarter and Full Year 2022

Aziyo Biologics, Inc. has completed a Follow-on Equity Offering in the amount of $11.1625 million.

Aziyo Biologics, Inc. has completed a Follow-on Equity Offering in the amount of $11.1625 million.

Aziyo Biologics, Inc. Revises Revenue Guidance for the Full Year 2022

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Aziyo Biologics, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Aziyo Biologics, Inc. Appoints David Colpman to Board of Directors and Audit Committee

Aziyo Biologics, Inc. Promotes Jeff Hamet to Senior Vice President of Finance

Aziyo Biologics, Inc. Appoints Michelle Leroux Williams, Ph.D as Chief Scientific Officer

Aziyo Biologics appoints Williams as Chief Scientific Officer

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Aziyo Biologics, Inc. Announces Randal Mills as Chief Executive Officer

Aziyo Biologics names co-founder C. Randal Mills as permanent CEO

Aziyo Biologics, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Aziyo Biologics, Inc. Appoints C. Randal (Randy) Mills, Ph.D. as Interim President

Aziyo Biologics Receives a Written Notice from the Listing Qualifications Staff of The Nasdaq Stock Market LLC Regarding Continued Listing Requirement Under Nasdaq Listing Rule 5450(b)(1)(A)

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Aziyo Biologics, Inc. Confirms Financial Guidance for Year 2022

Price target decreased to US$13.00

Aziyo Biologics, Inc. to Report Q1, 2022 Results on May 09, 2022

Aziyo Biologics, Inc., Annual General Meeting, Jun 07, 2022

Aziyo Biologics, Inc. Announces FDA 510(k) Submission for CanGaroo® RM, its Next-Generation Biomaterial Envelope Enhanced with Antibiotics

Consensus EPS estimates fall by 10%

Analyse CEO-vergoeding

CEO